Finnish Brainshake has raised €2 million in Series B funding. The company closed €3.5 million Series A funding in July. Combined total funding for the company during the past two years aggregates now to 7.5 million euros. The collected equity will be utilized to advance regulatory approval and internationalization of Brainshake’s blood analysis service.

Brainshake’s blood analysis service provides more than 220 biomarkers from a single blood sample – 50 times more than commonly used laboratory methods. Biomarkers reflect the health state of an individual and enables predicting disease risk for chronic diseases. As a part of the 2 million-euro investment, TJP Consulting, a Finnish growth company accelerator, joins Brainshake as a strategic partner in building the company’s global operations.

“The disruptive power of Brainshake’s technology relies in extensive scientific background and scalability allowing the blood analysis to be used in routine healthcare. It’s a great opportunity to join Brainshake’s team in building the company’s global operations. Brainshake has a unique position to disrupt routine blood sample analysis globally in chronic diseases, such as diabetes and CVD”, says Tuomas Poskiparta, Chairman, TJP Consulting.

The lead investor of Brainshake’s Round A, Finnish growth venture Cor Group, also participated in Round B strengthening their role as a shareholder and long-term strategic partner. Brainshake is also a member of one of the world’s biggest health-focused start-up accelerators StartUp Health.

Brainshake’s blood analysis, backed up by 100 peer-reviewed scientific publications, is already in use at leading universities globally.

“Our technology has been proven by peer-reviewed science and the epidemiological studies show the power of our data in risk assessment of chronic diseases. Now we are bringing the technology to routine healthcare with the ultimate target to enable prevention of the world’s number one health problem”, says Teemu Suna, CEO, Brainshake.

Helsinki-based Brainshake has 15 employees in Finland.

Further information:

Teemu Suna, CEO, Brainshake, tel. +358 40 196 1669,

About Brainshake 
Brainshake Ltd. is a blood analysis company redesigning global healthcare through the power of metabolic profiling. With technology backed up by 100 peer-reviewed biomedical publications, Brainshake provides disruptive blood analysis service to advance precision medicine in chronic diseases. For more information please visit